Thalassemia Pipeline Analysis 2019 (H1)

Thalassemia Pipeline Analysis report covers 18 drugs currently in different phases of development. Thalassemia is a genetic/inherited blood disorder which is characterized by less haemoglobin and fewer red blood cells in the human body than the normal. A person having mild thalassemia may not need treatment. In severe condition, lesser haemoglobin the body and low number of red blood cells may lead to anaemia. Some of the symptoms include fatigue, pale or yellowish skin, and facial bone deformities among others. Two main types of thalassemia include Alpha and Beta Thalassemia.

The report provides Thalassemia treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.

Major industry players profiled as part of the report include Novartis, GlaxoSmithKline plc., Orchard Therapeutics, Acceleron Pharma, Inc., Imara Inc., CRISPR Therapeutics AG, Protagonist Therapeutics, Inc., and Errant Gene Therapeutics among others.

Scope:

• By Company
• By Phase
• By Molecule Type
• By Region
• By Route of Administration

1. Introduction

1.1. Research Methodology

1.2. Research Scope

1.2.1. Analysis by Company

1.2.2. Analysis by Phase

1.2.3. By Molecule Type

1.2.4. By region

2. Disease Overview

2.1.1. Introduction

2.1.2. Classification

2.1.3. Symptoms

2.1.4. Causes

2.1.5. Diagnosis

2.1.6. Treatment

2.1.7. Epidemiology

3. Executive Summary

4. Market Dynamics

4.1. Drivers

4.2. Restraints

4.3. Opportunities

5. Pipeline Analysis/Outlook

5.1. Analysis by Company

5.2. Analysis by Phase

5.2.1. Phase of Development

5.2.1.1. Introduction

5.2.1.1.1. Drug Profiling

• Drug Name

• Generic Name

• Synonyms

• Company

• Collaborator

• Route of administration

• Target 

• Mechanism of Action

• Technology

• Molecule type

• CAS Number

• Weight

• Chemical Formula

• IUPAC name

• ATC code

5.2.1.1.2. Strategic Developments

5.2.1.1.3. Clinical trials

5.2.1.1.4. Clinical trial results

5.2.1.1.5. Patents

5.2.1.1.6. Technology

5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph)

5.3. By Molecule type

5.4. Analysis by Region

6. Company Profiles

6.1. Novartis

6.2. GlaxoSmithKline plc.

6.3. Orchard Therapeutics

6.4. Acceleron Pharma, Inc. 

6.5. Celgene Corporation

6.6. Sanofi Genzyme

6.7. Sangamo Therapeutics 

6.8. Bluebird bio, Inc.

6.9. La Jolla Pharmaceutical Company

6.10. Ionis Pharmaceuticals Inc.

6.11. Imara Inc.

6.12. CRISPR Therapeutics AG

6.13. Protagonist Therapeutics, Inc.

6.14. Errant Gene Therapeutics

6.15. Agios Inc.

6.16. Silence Therapeutics

6.17. CSL Behring

6.18. Editas Medicine

6.19. Vifor Pharma

6.20. Kiadis Pharma

List of Tables

List of Figures

Novartis

GlaxoSmithKline plc.

Orchard Therapeutics

Acceleron Pharma, Inc.

Celgene Corporation

Sanofi Genzyme

Sangamo Therapeutics

Bluebird bio, Inc.

La Jolla Pharmaceutical Company

Ionis Pharmaceuticals Inc.

Imara Inc.

CRISPR Therapeutics AG

Protagonist Therapeutics, Inc.

Errant Gene Therapeutics

Agios Inc.

Silence Therapeutics

CSL Behring

Editas Medicine

Vifor Pharma

Kiadis Pharma